Science Explorer Back to mapMap
Discussion
Company · Tokyo · Japan

Astellas Pharma (Japan)

In research, Astellas Pharma (Japan) stands highest in Medicine (#5,080 of 8,541 worldwide) and Health Sciences (#6,037 of 9,902 worldwide), 2022-now.

World rank, 2022-now
#15,812
of 22,385 · #19,114 all time
Rank in Japan
#465
of 924
Research works
1.5k
▼ 39% vs 2018-21
Citations
33k
22.4 per fractional work
Top-10% rate
8.9%
all institutions 10.0%
vs its own fields
0.98×
1.00× is exactly expected
Open access
40%
world 40%
International
19%
world 18%

What is Astellas Pharma (Japan) known for in research?

The fields where it stands highest, 2022-now, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorksAll time
MedicineField #5,080 of 8,541 11.0%77 #6032
Health SciencesDomain #6,037 of 9,902 10.7%80 #7089

Each strip is that field's whole ranked pool, with the notch where Astellas Pharma (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).

Which fields of science does Astellas Pharma (Japan) work in?

In 2022-now, 49% of research at Astellas Pharma (Japan) is in Health Sciences, 34% in Life Sciences. Its largest fields are Medicine (47%), Biochemistry, Genetics and Molecular Biology (21%), Engineering (5%). It does 2.4× the world's share of Life Sciences.

Health Sciences: 88 fractional works · 48.8% of its workMedicine: 86 fractional works · 47.2% of its workOncology: 14 fractional works · 8.0% of its workHematology: 8 fractional works · 4.3% of its workSurgery: 8 fractional works · 4.2% of its workEndocrinology, Diabetes and Metabolism: 7 fractional works · 3.6% of its workPulmonary and Respiratory Medicine: 6 fractional works · 3.1% of its workRheumatology: 5 fractional works · 2.7% of its workRadiology, Nuclear Medicine and Imaging: 5 fractional works · 2.5% of its workEpidemiology: 4 fractional works · 2.2% of its workPhysiology: 3 fractional works · 1.7% of its workGenetics: 3 fractional works · 1.4% of its workOphthalmology: 3 fractional works · 1.4% of its workPublic Health, Environmental and Occupational Health: 2 fractional works · 1.2% of its workPharmacology: 2 fractional works · 1.0% of its workImmunology and Allergy: 2 fractional works · 0.9% of its workUrology: 2 fractional works · 0.9% of its workNephrology: 2 fractional works · 0.8% of its workCardiology and Cardiovascular Medicine: 1 fractional works · 0.7% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 0.7% of its workGastroenterology: 1 fractional works · 0.7% of its workNeurology: 1 fractional works · 0.7% of its workPsychiatry and Mental health: 1 fractional works · 0.6% of its workPathology and Forensic Medicine: 1 fractional works · 0.6% of its workTransplantation: 1 fractional works · 0.5% of its workReproductive Medicine: 1 fractional works · 0.4% of its workHepatology: 1 fractional works · 0.4% of its workObstetrics and Gynecology: 1 fractional works · 0.4% of its workComplementary and alternative medicine: 1 fractional works · 0.4% of its workInfectious Diseases: 1 fractional works · 0.3% of its workEmergency Medicine: 0 fractional works · 0.2% of its workGeriatrics and Gerontology: 0 fractional works · 0.2% of its workSmaller subfields together: 1 fractional works · 0.4% of its workHealth Professions: 3 fractional works · 1.4% of its workGeneral Health Professions: 1 fractional works · 0.7% of its workMedical Laboratory Technology: 1 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.1% of its workVeterinary: 0 fractional works · 0.1% of its workDentistry: 0 fractional works · 0.1% of its workNursing: 0 fractional works · 0.0% of its workLife Sciences: 61 fractional works · 33.6% of its workBiochemistry, Genetics and Molecular Biology: 38 fractional works · 20.8% of its workMolecular Biology: 26 fractional works · 14.1% of its workGenetics: 4 fractional works · 2.5% of its workCancer Research: 2 fractional works · 1.2% of its workCell Biology: 2 fractional works · 1.0% of its workBiotechnology: 2 fractional works · 0.9% of its workBiophysics: 1 fractional works · 0.4% of its workPhysiology: 1 fractional works · 0.3% of its workBiochemistry: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNeuroscience: 8 fractional works · 4.3% of its workCellular and Molecular Neuroscience: 3 fractional works · 1.5% of its workNeurology: 2 fractional works · 1.1% of its workCognitive Neuroscience: 2 fractional works · 0.9% of its workEndocrine and Autonomic Systems: 1 fractional works · 0.6% of its workBiological Psychiatry: 0 fractional works · 0.2% of its workImmunology and Microbiology: 8 fractional works · 4.3% of its workImmunology: 6 fractional works · 3.4% of its workVirology: 1 fractional works · 0.6% of its workMicrobiology: 1 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 6 fractional works · 3.6% of its workPharmaceutical Science: 4 fractional works · 2.4% of its workPharmacology: 2 fractional works · 1.0% of its workSmaller subfields together: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 1 fractional works · 0.6% of its workFood Science: 1 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.3% of its workPhysical Sciences: 26 fractional works · 14.6% of its workEngineering: 9 fractional works · 5.1% of its workBiomedical Engineering: 5 fractional works · 2.5% of its workAerospace Engineering: 3 fractional works · 1.7% of its workElectrical and Electronic Engineering: 1 fractional works · 0.3% of its workSmaller subfields together: 1 fractional works · 0.5% of its workMathematics: 5 fractional works · 2.9% of its workStatistics and Probability: 5 fractional works · 2.8% of its workSmaller subfields together: 0 fractional works · 0.0% of its workComputer Science: 4 fractional works · 2.2% of its workComputational Theory and Mathematics: 2 fractional works · 0.9% of its workArtificial Intelligence: 1 fractional works · 0.4% of its workInformation Systems: 1 fractional works · 0.4% of its workSmaller subfields together: 1 fractional works · 0.5% of its workChemistry: 4 fractional works · 1.9% of its workOrganic Chemistry: 2 fractional works · 0.9% of its workAnalytical Chemistry: 1 fractional works · 0.5% of its workSpectroscopy: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workMaterials Science: 2 fractional works · 1.1% of its workMaterials Chemistry: 1 fractional works · 0.6% of its workBiomaterials: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workEnvironmental Science: 2 fractional works · 0.8% of its workEnvironmental Chemistry: 1 fractional works · 0.4% of its workEcology: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysics and Astronomy: 1 fractional works · 0.5% of its workAstronomy and Astrophysics: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workEarth and Planetary Sciences: 0 fractional works · 0.1% of its workSocial Sciences: 5 fractional works · 3.0% of its workEconomics, Econometrics and Finance: 3 fractional works · 1.7% of its workEconomics and Econometrics: 3 fractional works · 1.7% of its workSocial Sciences: 1 fractional works · 0.5% of its workEducation: 1 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workDecision Sciences: 1 fractional works · 0.4% of its workManagement Science and Operations Research: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPsychology: 1 fractional works · 0.4% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workBusiness, Management and Accounting: 0 fractional works · 0.1% of its workALL ITS WORKAstellas Pharma(Japan)181fractional works, 2022-now
Life Sciences34%Physical Sciences15%Health Sciences49%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 23 fields, with their numbers
    1. Medicine8647.2%
    2. Health Professions31.4%
    3. Veterinary00.1%
    4. Dentistry00.1%
    5. Nursing00.0%
    1. Biochemistry, Genetics and Molecular Biology3820.8%
    2. Neuroscience84.3%
    3. Immunology and Microbiology84.3%
    4. Pharmacology, Toxicology and Pharmaceutics63.6%
    5. Agricultural and Biological Sciences10.6%
    1. Engineering95.1%
    2. Mathematics52.9%
    3. Computer Science42.2%
    4. Chemistry41.9%
    5. Materials Science21.1%
    6. Environmental Science20.8%
    7. Physics and Astronomy10.5%
    8. Earth and Planetary Sciences00.1%
    1. Economics, Econometrics and Finance31.7%
    2. Social Sciences10.5%
    3. Decision Sciences10.4%
    4. Psychology10.4%
    5. Business, Management and Accounting00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.13× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.90× its world share, 38 worksBiochemistry, Geneti…Immunology and Microbiology: 4.28× its world share, 8 worksImmunology and Micro…Neuroscience: 2.66× its world share, 8 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 10.17× its world share, 6 worksPharmacology, Toxico…Chemistry: 1.24× its world share, 4 worksChemistryComputer Science: 0.28× its world share, 4 worksComputer ScienceEarth and Planetary Sciences: 0.08× its world share, 0 worksEarth and Planetary …Engineering: 0.34× its world share, 9 worksEngineeringEnvironmental Science: 0.17× its world share, 2 worksEnvironmental ScienceMaterials Science: 0.32× its world share, 2 worksMaterials ScienceMathematics: 2.43× its world share, 5 worksMathematicsPhysics and Astronomy: 0.21× its world share, 1 worksPhysics and AstronomyDentistry: 0.13× its world share, 0 worksDentistryHealth Professions: 0.53× its world share, 2 worksHealth ProfessionsMedicine: 2.45× its world share, 86 worksMedicineNursing: 0.08× its world share, 0 worksNursingVeterinary: 0.97× its world share, 0 worksVeterinaryBusiness, Management and Accounting: 0.02× its world share, 0 worksBusiness, Management…Decision Sciences: 0.38× its world share, 1 worksDecision SciencesEconomics, Econometrics and Finance: 0.78× its world share, 3 worksEconomics, Econometr…Psychology: 0.12× its world share, 1 worksPsychologySocial Sciences: 0.04× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 10.2×. Every wedge is a field page.

All 23 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics10.17×6 works
  2. Immunology and Microbiology4.28×8 works
  3. Biochemistry, Genetics and Molecular Biology3.90×38 works
  4. Neuroscience2.66×8 works
  5. Medicine2.45×86 works
  6. Mathematics2.43×5 works
  7. Chemistry1.24×4 works
  8. Veterinary0.97×0 works
  9. Economics, Econometrics and Finance0.78×3 works
  10. Health Professions0.53×2 works
  11. Decision Sciences0.38×1 works
  12. Engineering0.34×9 works
  13. Materials Science0.32×2 works
  14. Computer Science0.28×4 works
  15. Physics and Astronomy0.21×1 works
  16. Environmental Science0.17×2 works
  17. Agricultural and Biological Sciences0.13×1 works
  18. Dentistry0.13×0 works
  19. Psychology0.12×1 works
  20. Earth and Planetary Sciences0.08×0 works
  21. Nursing0.08×0 works
  22. Social Sciences0.04×1 works
  23. Business, Management and Accounting0.02×0 works

Who are the top researchers at Astellas Pharma (Japan)?

Ranked on the quality score, Mitsuyuki Matsumoto, Héctor Aviña and Alla Verlinsky lead among researchers whose main affiliation is Astellas Pharma (Japan).

  1. 1 Mitsuyuki Matsumoto Japan · #782,954 worldwide 7.2k citations · 147 works
  2. 2 Héctor Aviña Japan · #805,461 worldwide 1.3k citations · 91 works
  3. 3 Alla Verlinsky Japan · #1,262,238 worldwide 1.4k citations · 35 works
  4. 4 Takahide Ohishi Japan · #1,337,676 worldwide 3.1k citations · 44 works
  5. 5 Masahiko Hayakawa Japan · #1,408,186 worldwide 1.8k citations · 45 works
  6. 6 Mitsuhiro Rokuda Japan · #1,491,019 worldwide 1k citations · 21 works
  7. 7 Tatsuya Kawase Japan · #1,541,808 worldwide 1.5k citations · 152 works
  8. 8 Kiyomitsu Katsumata Japan · #1,566,694 worldwide 761 citations · 21 works
  9. 9 Masato Kobori Japan · #1,627,814 worldwide 3.5k citations · 45 works
  10. 10 Katsunori Tajinda Japan · #1,787,838 worldwide 1.2k citations · 40 works
All ranked researchers at Astellas Pharma (Japan)

What are the most cited papers from Astellas Pharma (Japan)?

The most cited paper from Astellas Pharma (Japan) is "Identification of a Primary Target of Thalidomide Teratogenicity" (Takumi Ito, Hideki Ando, Takayuki Suzuki et al., 2010), with 2,136 citations. Next come "Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial" (1,375) and "Linking the p53 tumour suppressor pathway to somatic cell reprogramming" (1,136).

Most cited papers
#PaperReleasedCitations
1 Identification of a Primary Target of Thalidomide Teratogenicity Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science 11 Mar 2010 2,136
2 Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial Piet Ost, Dries Reynders, Karel Decaestecker et al. · Journal of Clinical Oncology 14 Dec 2017 1,375
3 Linking the p53 tumour suppressor pathway to somatic cell reprogramming Teruhisa Kawamura, Jotaro Suzuki, Yunyuan V. Wang et al. · Nature Open access Aug 2009 1,136
4 The genetic architecture of the human cerebral cortex Katrina L. Grasby et al. · Science Open access362 authors 19 Mar 2020 910
5 A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing Deng Pan, Aya Kobayashi, Peng Jiang et al. · Science Open access 4 Jan 2018 880
All 58 most cited papers, with filters and sorting

Which keywords describe research at Astellas Pharma (Japan)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Immunotherapy, Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Heart Failure, Oxidative Stress and Tumor Microenvironment.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Inflammation13▲ 3.3×35 topics
  2. Immunotherapy9▲ 6.5×12 topics
  3. Oxidative Stress8▲ 2.8×22 topics
  4. Cancer7▲ 2.8×25 topics
  5. Quality of Life7▲ 2.5×12 topics
  6. Cardiovascular Disease6▲ 3.0×14 topics
  7. Glycosylation6▲ 31×3 topics
  8. Monoclonal Antibodies6▲ 38×3 topics
  9. Chemotherapy6▲ 4.6×11 topics
  10. Heart Failure6▲ 6.8×6 topics
  11. Therapeutic Antibodies6▲ 43×2 topics
  12. Biomarkers5▲ 4.2×9 topics
  13. Tumor Microenvironment5▲ 6.4×7 topics
  14. Cancer Therapy5▲ 5.0×9 topics
  15. Cell Culture5▲ 21×2 topics
  16. Clinical Guidelines4▲ 8.5×5 topics
  17. Tumor Regression4▲ 21×2 topics
  18. Breast Cancer4▲ 9.3×6 topics
  19. Transcriptional Regulation4▲ 14×7 topics
  20. Cancer Immunotherapy4▲ 15×3 topics
  21. Regenerative Medicine4▲ 8.8×3 topics
  22. Bayesian Methods4▲ 44×2 topics
  23. Glycemic Control4▲ 14×4 topics
  24. Insulin Therapy4▲ 18×3 topics
  25. Type 2 Diabetes4▲ 9.6×3 topics
  26. Cardiovascular Risk4▲ 6.8×6 topics
  27. Gene Therapy4▲ 11×5 topics
  28. Lymphoma4▲ 14×3 topics
  29. Autoantibodies4▲ 8.7×7 topics
  30. CAR T Cells4▲ 28×1 topic
  31. Chimeric Antigen Receptor4▲ 28×1 topic
  32. Cancer Treatment4▲ 8.4×6 topics
  33. Biopharmaceuticals4▲ 38×3 topics
  34. Pharmacokinetics4▲ 7.3×4 topics
  35. Antibody Engineering3▲ 34×1 topic
  36. Fc Receptors3▲ 34×1 topic
  37. Adaptive Designs3▲ 87×1 topic
  38. False Discovery Rate3▲ 87×1 topic
  39. Cardiovascular Outcomes3▲ 31×1 topic
  40. Glucose Control3▲ 31×1 topic

Which research topics does Astellas Pharma (Japan) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Statistical Methods in Clinical Trials and Diabetes Treatment and Management.

  1. 1 CAR-T cell therapy research Oncology 4 works
  2. 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 3 works
  3. 3 Statistical Methods in Clinical Trials Statistics and Probability 3 works
  4. 4 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 3 works
  5. 5 3D Printing in Biomedical Research Biomedical Engineering 3 works
  6. 6 Drug Solubulity and Delivery Systems Pharmaceutical Science 2 works
  7. 7 Protein purification and stability Molecular Biology 2 works
  8. 8 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 2 works
  9. 9 Erythropoietin and Anemia Treatment Hematology 2 works
  10. 10 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 2 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available40.1%not open59.9%

World: 40% of research is openly available.

with international co-authors19.4%domestic only80.6%

World: 18% is written across borders.

How has Astellas Pharma (Japan)'s research output changed?

Output in 2022-2025 was 39% lower than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Astellas Pharma (Japan) as a percentage of every work published that year, 0.00051% in 2024.

still counting0.0020%0.0040%0.0060%Astellas Pharma (Japan)0.00079% in 20251990200020102020

Fractional works of Astellas Pharma (Japan) over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year, against all institutions in the same year.

still counting5%10%15%all institutions10.0% in 2025Astellas Pharma (Japan)9.3% in 202520102020

Of each year's output, the share that reached the world's 10% most cited for its field and year. Peak 14.6% in 2024.

Other research institutions in Tokyo

All research institutions in Tokyo

Share Astellas Pharma (Japan)'s ranking

Astellas Pharma (Japan) on Science Explorer

A card with Astellas Pharma (Japan)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Astellas Pharma (Japan). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.